Surgical Strategy for Head and Neck Adenoid Cystic Cancer

Completed

• Conditions: Adenoid Cystic Carcinoma

• Registration Number: NCT06778915
• Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Brief Summary

To investigate the relationship between surgical margins and outcomes across different tumor stages, in order to provide evidence and guidance for refining stage-specific surgical approaches.

Detailed Description

Adenoid cystic carcinoma of the head and neck (HNACC) presents unique surgical challenges due to its propensity for perineural spread and proximity to critical craniofacial structures. While surgical resection remains the cornerstone of treatment, determining the optimal extent of resection to balance oncologic control and functional preservation requires further investigation. The investigator aimed to investigate the relationship between surgical margins and outcomes across different tumor stages, in order to provide evidence and guidance for refining stage-specific surgical approaches.

Study Timeline

• Study Start: 2016-01-01
• Primary Completion: 2022-12-31
• Study Completion: 2024-08-30
• Status Verified: 2025-01
• Study First Submitted: 2025-01-09
• Study First Submitted QC: 2025-01-14
• Last Update Submitted: 2025-01-14
• Study First Posted: 2025-01-16
• Last Update Posted: 2025-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 309

Inclusion Criteria

• patients who underwent surgical resection with curative intent and PORT.

Exclusion Criteria

• underwent only biopsy, presented with distant metastases or second primary malignancies at initial diagnosis, had incomplete clinical or histopathologic data, or had histologic evidence of high-grade transformation.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Local control	5 year	defined as the absence of tumor persistence, recurrence, or progression at the primary tumor site following the completion of treatment, assessed by clinical examination and imaging at designated follow-up intervals.

Secondary Outcome Measures

Name	Time	Method
Locoregional Recurrence-Free Survival (LRRFS)	5 year	time from treatment initiation to either locoregional recurrence or death from any cause
Overall Survival (OS)	5 year	time from treatment initiation to death from any cause
Distant Metastasis-Free Survival (DMFS)	5 year	time from treatment initiation to either distant metastasis or death from any cause